Jusvinza

4 trials

Sponsors

Center for Genetic Engineering and Biotechnology (CIGB), Havana, Center for Genetic Engineering and Biotechnology (CIGB), Center for Genetic Engineering and Biotechnology (CGIB), the Havana

Conditions

Acute Respiratory Distress SyndromeAcute Respiratory Distress by Covid-19 COVID-19 SARS-CoV-2Severe PneumoniaSystemic inflammation by Covid-19 COVID-19 SARS-CoV-2

Phase 2

Active, not recruitingRPCEC00000393

Center for Genetic Engineering and Biotechnology (CIGB), HavanaAcute Respiratory Distress by Covid-19 COVID-19 SARS-CoV-2

Start: 2021-10-30Target: 108Updated: 2026-08-10

Phase 3

Jusvinza in Severe Patients with Acquired Community Pneumonia

Active, not recruitingRPCEC00000411

Center for Genetic Engineering and Biotechnology (CGIB), the HavanaSevere Pneumonia

Start: 2022-11-07Target: 60Updated: 2026-08-10

Efficacy and safety of Jusvinza treatment in patients with acute respiratory distress syndrome. Phase II/III

Active, not recruitingRPCEC00000422

Center for Genetic Engineering and Biotechnology (CIGB)Acute Respiratory Distress Syndrome

Start: 2023-05-22Updated: 2026-08-10

Unknown Phase

Retrospective observational study of the administration of Jusvinza, for the management of COVID-19 at the Hospital “Dr. Luis Diaz Soto”.

Active, not recruitingRPCEC00000394

Center for Genetic Engineering and Biotechnology (CIGB)Systemic inflammation by Covid-19 COVID-19 SARS-CoV-2

Start: 2021-03-20Target: 348Updated: 2026-08-10